ProPhase Labs, Inc. Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities
ProPhase Labs, Inc. (PRPH) reported Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities of 0 shares for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-10.
Discontinued › Income Statement › Earnings Per Share
us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities · last filed 2024-05-10
- ProPhase Labs, Inc. incremental common shares attributable to dilutive effect of conversion of debt securities for the quarter ending 2024-03-31 was 0.00 shares, a 100.00% decline year-over-year.
- ProPhase Labs, Inc. incremental common shares attributable to dilutive effect of conversion of debt securities for the quarter ending 2023-09-30 was 0.00 shares, a 100.00% decline year-over-year.
- ProPhase Labs, Inc. incremental common shares attributable to dilutive effect of conversion of debt securities for the quarter ending 2023-06-30 was 0.00 shares, a 100.00% decline year-over-year.
- ProPhase Labs, Inc. incremental common shares attributable to dilutive effect of conversion of debt securities for the quarter ending 2023-03-31 was 240.00K shares, a 29900.00% increase year-over-year.
- ProPhase Labs, Inc. incremental common shares attributable to dilutive effect of conversion of debt securities for fiscal 2023 was 0.00 shares, a 100.00% decline from fiscal 2022.
- ProPhase Labs, Inc. incremental common shares attributable to dilutive effect of conversion of debt securities for fiscal 2022 was 240.00K shares, a 76.00% decline from fiscal 2021.
- ProPhase Labs, Inc. incremental common shares attributable to dilutive effect of conversion of debt securities for fiscal 2021 was 1.00M shares.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 3 month | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 3 month as first filed | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 6 month | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 9 month | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 9 month as first filed | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 12 month |
|---|---|---|---|---|---|---|
| 2024-03-31 | 0.00 shares 10-Q · filed 2024-05-10 | |||||
| 2023-12-31 | 0.00 shares 10-K · filed 2024-03-29 | |||||
| 2023-09-30 | 0.00 shares 10-Q · filed 2023-11-13 | 0.00 shares 10-Q · filed 2023-11-13 | ||||
| 2023-06-30 | 0.00 shares 10-Q · filed 2023-08-11 | 0.00 shares 10-Q · filed 2023-08-11 | ||||
| 2023-03-31 | 240.00K shares 10-Q · filed 2024-05-10 | 240.00 shares 10-Q · filed 2023-05-12 | ||||
| 2022-12-31 | 240.00K shares 10-K · filed 2024-03-29 | |||||
| 2022-09-30 | 800.00K shares 10-Q · filed 2023-11-13 | 800.00 shares 10-Q · filed 2022-11-10 | 800.00K shares 10-Q · filed 2023-11-13 | 800.00 shares 10-Q · filed 2022-11-10 | ||
| 2022-06-30 | 800.00 shares 10-Q · filed 2023-08-11 | 800.00 shares 10-Q · filed 2023-08-11 | ||||
| 2022-03-31 | 800.00 shares 10-Q · filed 2023-05-12 | |||||
| 2021-12-31 | 1.00M shares 10-K · filed 2023-03-29 | |||||
| 2021-03-31 | 458.00 shares 10-Q · filed 2022-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |